Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature

被引:0
作者
Rika Yuliwulandari
Qomariyah Sachrowardi
Nao Nishida
Miwa Takasu
Lilian Batubara
Tri Panjiasih Susmiarsih
Jecti Teguh Rochani
Riyani Wikaningrum
Risa Miyashita
Taku Miyagawa
Abdul Salam Mudzakir Sofro
Katsushi Tokunaga
机构
[1] University of Tokyo,Department of Human Genetics, Graduate School of Medicine
[2] Yarsi University,Faculty of Medicine
来源
Journal of Human Genetics | 2008年 / 53卷
关键词
Polymorphisms; Acetylation; Promoter; Indonesian;
D O I
暂无
中图分类号
学科分类号
摘要
Polymorphisms of arylamine N-acetyltransferase 2 (NAT2) are reportedly associated with the risk of drug toxicities and development of various diseases. The present study examined NAT2 polymorphisms in both promoter and coding regions in the Indonesian population using PCR direct sequencing. The promoter and coding regions of NAT2 displayed 23 polymorphisms/variations, including eight new ones. Seven haplotypes in the promoter region and six haplotypes in the coding region were inferred. The haplotypes in promoter and coding regions showed limited combinations, and 13 combined haplotypes were inferred. The most frequent haplotypes were U1 (38.9%), U2 (33.5%) in the promoter region and NAT2*4 (37.3%), NAT2*6A (36.8%) in the coding region. When converted to predicted phenotypes, the studied population comprised 65.4% rapid acetylators and 35.6% slow acetylators according to bimodal distribution. According to trimodal distribution, frequencies of predicted phenotypes were 13.6, 50.8 and 35.6% for rapid, intermediate and slow acetylators, respectively. Frequencies of NAT2 alleles for the Indonesian population resembled those of other Southeast Asian populations. We also propose a new NAT2 nomenclature composed of haplotypes in the promoter region and conventional NAT2 haplotypes in the coding region, symbolized by NAT2*4.U1, NAT2*4.U2, NAT2*4.U3, NAT2*4.U5, NAT2*4.U6, NAT2*4.U7, NAT2*6A.U1, NAT2*7B.U2, NAT2*7B.U3, NAT2*5B.U1, NAT2*5B.U4, NAT2*12A.U4 and NAT2*13.U1.
引用
收藏
页码:201 / 209
页数:8
相关论文
共 234 条
  • [1] Bakayev VV(2004)Arylamine Eur J Clin Pharmacol 60 467-471
  • [2] Mohammadi F(2000)-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals Mov Disord 15 30-35
  • [3] Bahadori M(1993)Detailed genotyping demonstrates association between the slow acetylator genotype for Carcinogenesis 14 1689-1692
  • [4] Sheikholslami M(1990)-acetyltransferase 2 (NAT2) and familial Parkinson’s disease DNA Cell Biol 9 193-203
  • [5] Javeri A(1991)Genotype/phenotype discordance for human arylamine Proc Natl Acad Sci USA 88 5237-5241
  • [6] Masjedi MR(2002)-acetyltransferase 2 (NAT2) reveals a new slow-acetylator allele common in African–Americans Pharmacogenomics J 2 30-42
  • [7] Velayati AA(1995)Human Am J Hum Genet 57 581-592
  • [8] Bandmann O(2006)-acetyltransferase genes: isolation, chromosomal localisation and functional expression Eur J Clin Pharmacol 62 355-359
  • [9] Vaughan JR(2001)Molecular mechanism of slow acetylation of drugs and carcinogens in humans Drug Metab Dispos 29 606-610
  • [10] Holmans P(1999)Pharmacogenetics of the arylamine Cancer Epidemiol Biomarkers Prev 8 683-692